Clinical trials
Renal Cell Cancer Metastatic clinical trials
Below are recruiting renal cell cancer metastatic clinical trials, each written for real people, not researchers. We’re tracking 606 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07390838RecruitingPhase 1
Study of SH009 for advanced solid tumors
This trial tests an investigational drug called SH009 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective.
ShanghaiAges 18 years+ - NCT07402109Recruiting
Precise guided radiation therapy for kidney cancer
This trial tests a new type of precise radiation therapy for kidney cancer. It uses a special scanner to guide the treatment without needing a marker, which may make the procedure quicker and more comfortable.
Rotterdam, South HollandAges 18 years+ - NCT07405086RecruitingPhase 4
Morning vs. afternoon immunotherapy for advanced solid tumors
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Portland, OregonAges 18 years+ - NCT07407465RecruitingPhase 2
Study of a new drug combo for advanced HER2-positive colorectal cancer
This trial tests a combination of three drugs (trastuzumab deruxtecan, capecitabine, and bevacizumab) as the first treatment for people with HER2-positive colorectal cancer that has spread or cannot be removed by surgery. The goal is to see if this combination can shrink tumors and help patients live longer.
LyonAges 18 years+ - NCT07410494RecruitingPhase 1/Phase 2
Personalized donor cell therapy for advanced solid tumors
This trial tests a personalized cell therapy (CAR-NK) using donor immune cells that are engineered to find and attack one or two markers on advanced solid tumors. It may be an option for people whose tumors have these specific markers and have exhausted other treatments.
Beijing, Beijing MunicipalityAges 8–85 - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07432295RecruitingPhase 2
Givastomig plus nivolumab and chemo for advanced stomach cancer
This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.
Goodyear, ArizonaAges 18 years+ - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT07540260Recruiting
Imaging-Guided Radiation Therapy for Advanced Kidney Cancer
This trial uses two types of PET scans to better target radiation therapy in patients with advanced clear cell kidney cancer that has spread or returned. The goal is to combine radiation with standard drug treatments to improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07555210Recruiting
Bone Density Changes During Cancer Immunotherapy
This study tracks how a type of cancer treatment called anti-PD-1 immunotherapy affects bone strength over time. Researchers want to understand whether this treatment causes bone density loss and help develop ways to protect bones during cancer care.
Nashville, TennesseeAges 18 years+ - NCT07593820RecruitingPhase 1
CAR-T Cell Study for Advanced HER2-Positive Cancers
This early-stage trial tests a new type of immune cell therapy called CAR-T cells, which are designed to recognize and attack cancer cells that have a protein called HER2. The cells are made from your own immune cells, trained in the laboratory, and given back to you. The study evaluates how safe the treatment is and whether it can shrink tumors.
Barcelona, CataloniaAges 18 years+ - NCT07641049RecruitingPhase 1
CAR-NK Cell Therapy for Advanced Prostate Cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight advanced prostate cancer that has stopped responding to hormone treatments. The cells are engineered to recognize and attack cancer cells that have specific markers (PSMA and PSCA) on their surface.
Shenzhen, GuangdongAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
San Francisco, CaliforniaAges 18 years+ - NCT06747832Enrolling by invitationEarly Phase 1
INK cells after chemoradiation for small cell lung cancer
This trial tests whether adding a special immune cell called iNK cells after standard chemoradiation can help keep small cell lung cancer from coming back.
Weifang, Shandong Province, China.Ages 18–75 - NCT06004336RecruitingPhase 2
Maintenance therapy after radiation for limited spread kidney cancer
This trial tests whether giving a maintenance medication (pembrolizumab) after targeted radiation helps keep kidney cancer that has spread to a few spots (5 or fewer) from growing. You would receive radiation to each spot and then be randomly assigned to receive either the medication or a placebo (inactive substance) for up to about 2 years.
Houston, TexasAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Tucson, ArizonaAges 18 years+ - NCT06008925RecruitingPhase 1/Phase 2
VG161 plus nivolumab for advanced gastric cancer
This trial tests a new combination therapy (VG161, a herpes-based virus therapy, plus nivolumab) for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two previous treatments, including a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–75 - NCT01050504Recruiting
Donate blood and tissue to study recurrent or metastatic cancers
This study collects and studies blood and, when possible, small tissue samples from people with prostate or bladder/urothelial cancer that has come back or spread. The goal is to better understand these cancers and support future research that may lead to better care.
Seattle, WashingtonAges 18 years+ - NCT06889649RecruitingPhase 2
SBRT plus immunotherapy and targeted therapy for kidney cancer
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT07744256RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for relapsed small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Omaha, NebraskaAges 18 years+ - NCT06332755RecruitingPhase 1
Study of LB-LR1109 alone and with atezolizumab for cancer
This trial tests a new drug called LB-LR1109, alone or with atezolizumab, for adults with certain advanced solid tumors, including non-small cell lung cancer. It's for people whose cancer has worsened after standard treatments or who cannot have those treatments.
Fairfax, VirginiaAges 18 years+ - NCT07480213RecruitingPhase 1/Phase 2
CAR-NK cell therapy for relapsed small cell lung cancer
This trial tests a new type of immunotherapy called dual-target CAR-NK cells for people with small cell lung cancer that has returned or not responded to treatment. The treatment uses your own immune cells, modified in a lab, to better recognize and attack cancer cells.
Shenzhen, GuangdongAges 18–75 - NCT06936527Enrolling by invitationPhase 1/Phase 2
Combination therapy for metastatic colorectal cancer with RAS mutation
This trial tests a new drug called XS-03 combined with standard chemotherapy and bevacizumab for people with metastatic colorectal cancer that has a specific genetic change called a RAS mutation. It aims to see if this combination is more effective than current treatments.
BeijingAges 18–70
Hear when a new Renal Cell Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for renal cell cancer metastatic?
- Yes. Clin2 currently lists 606 recruiting renal cell cancer metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a renal cell cancer metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a renal cell cancer metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.